GlassScriptPhysician profile
Erik D Ebbing
NPI 1831503028
$6,314.92
in general payments reported to CMS, 2019-2025
24 companies · $2,071 in 2025
The $2,071 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $260 · 2021: $174 · 2022: $32.87 · 2023: $1,159 · 2024: $2,170 · 2025: $2,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,399.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,216.63 | 2024-2025 | Izervay |
| Bausch & Lomb Americas INC. | $979.63 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Glaukos Corporation | $815.62 | 2021-2025 | Idosetr, Idose |
| Abbvie INC. | $669.90 | 2023-2025 | Xen Glaucoma Treatment System, Vuity, Durysta |
| Alcon Vision LLC | $651.71 | 2021-2025 | Clareon, Rocklatan, Eysuvis |
| Tarsus Pharmaceuticals, INC. | $420.76 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $418.19 | 2019-2023 | |
| Oyster Point Pharma, INC. | $226.81 | 2023-2024 | Tyrvaya, Ryzumvi |
| Biotissue Holdings INC. | $130.98 | 2025 | |
| Sun Pharmaceutical Industries INC. | $109.87 | 2021-2025 | Cequa |
| Mallinckrodt Enterprises LLC | $106.01 | 2019 | |
| Spark Therapeutics, INC. | $91.82 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $79.65 | 2020-2025 | Eylea Hd |
| Amgen INC. | $67.50 | 2024 | Tepezza |
| Dompe US, INC. | $60.68 | 2025 | Oxervate |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $57.89 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $44.06 | 2019 | |
| Thea Pharma INC. | $39.95 | 2023-2025 | Iyuzeh |
| Lumenis, INC | $26.24 | 2021 | |
| Coherus Oncology, INC. | $24.57 | 2023 | |
| Kala Pharmaceuticals, INC. | $21.98 | 2020 | |
| Ocular Therapeutix, INC. | $21.80 | 2023 | Dextenza |
| Shire North American Group INC | $19.21 | 2019 | |
| Coopervision INC. | $13.46 | 2025 | Myday Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Ebbing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.